Diabetes mellitus is a chronic metabolic disease associated with high cardiovascular risk. Sodium glucose transporter 2 inhibitors（SGLT2i）are a new type of hypoglycemic drugs that can inhibit the absorption of glucose from the proximal tubule of the kidney，and then decrease blood sugar. SGLT2i can reduce HbA1c and have good effects on blood pressure，blood lipid，body weight and uric acid. Importantly，numerous clinical trials have demonstrated the cardioprotective effect of SGLT2i in patients with diabetes. The main mechanism is to affect cardiac remodeling，reduce ventricular load，improve cardiomyocyte metabolism and change adipokine production. This article reviews the effect of SGLT2i on the prognosis of cardiovascular disease in patients with diabetes mellitus.